PriceTargets.com logo

Hepion Pharmaceuticals - HEPA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.37 As of 04/26/2024 01:00 AM ET
▲ +0.08 (6.20%)

This chart shows the closing price for HEPA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hepion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HEPA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HEPA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Hepion Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.37.

This chart shows the closing price for HEPA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Hepion Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2023Brookline Capital ManagementDowngradeBuy ➝ HoldLow
1/31/2023Brookline Capital ManagementReiterated RatingBuyLow
1/23/2023Alliance Global PartnersInitiated CoverageBuyLow
2/28/2022Cantor FitzgeraldInitiated CoverageOverweight$70.00High
1/26/2022Brookline Capital ManagementReiterated RatingBuyLow
12/1/2020Roth CapitalLower Target$280.00 ➝ $160.00Low
7/20/2020Roth CapitalReiterated RatingBuyHigh
11/7/2019Roth CapitalReiterated RatingBuyMedium
11/7/2019Roth CapitalInitiated CoverageBuy$180.00N/A
(Data available from 4/26/2019 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/29/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/29/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Hepion Pharmaceuticals logo
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Read More

Today's Range

Now: $1.37
Low: $1.27
High: $1.44

50 Day Range

MA: $2.30
Low: $1.29
High: $3.17

52 Week Range

Now: $1.37
Low: $1.22
High: $20.66

Volume

39,627 shs

Average Volume

73,373 shs

Market Capitalization

$7.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Hepion Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Hepion Pharmaceuticals in the last twelve months: Brookline Capital Management.
View the latest analyst ratings for HEPA.

What is the current price target for Hepion Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Hepion Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hepion Pharmaceuticals in the next year.
View the latest price targets for HEPA.

What is the current consensus analyst rating for Hepion Pharmaceuticals?

Hepion Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HEPA, but not buy more shares or sell existing shares.
View the latest ratings for HEPA.

What other companies compete with Hepion Pharmaceuticals?

Other companies that are similar to Hepion Pharmaceuticals include Cyclerion Therapeutics, Virios Therapeutics, Molecular Templates, Universe Pharmaceuticals and NuCana. Learn More about companies similar to Hepion Pharmaceuticals.

How do I contact Hepion Pharmaceuticals' investor relations team?

Hepion Pharmaceuticals' physical mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The company's listed phone number is (732) 902-4000 and its investor relations email address is [email protected]. The official website for Hepion Pharmaceuticals is www.hepionpharma.com. Learn More about contacing Hepion Pharmaceuticals investor relations.